Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer

PURPOSE: Cyclophosphamide, epirubicin, and fluorouracil (CEF) and doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) are commonly used adjuvant regimens in women with early breast cancer. In a previous trial in women with locally advanced breast cancer, 3 months of high-dose epirubicin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Burnell, Margot, Levine, Mark N., Chapman, Judith-Anne W., Bramwell, Vivien, Gelmon, Karen, Walley, Barbara, Vandenberg, Ted, Chalchal, Haji, Albain, Kathy S., Perez, Edith A., Rugo, Hope, Pritchard, Kathleen, O'Brien, Patti, Shepherd, Lois E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2799234/
https://ncbi.nlm.nih.gov/pubmed/19901117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.1077
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados